These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma. Loosen SH; Roderburg C; Kauertz KL; Pombeiro I; Leyh C; Benz F; Vucur M; Longerich T; Koch A; Braunschweig T; Ulmer TF; Heidenhain C; Tacke F; Binnebösel M; Schmeding M; Trautwein C; Neumann UP; Luedde T J Hepatol; 2017 Oct; 67(4):749-757. PubMed ID: 28668580 [TBL] [Abstract][Full Text] [Related]
4. Evolution of the Experimental Models of Cholangiocarcinoma. Massa A; Varamo C; Vita F; Tavolari S; Peraldo-Neia C; Brandi G; Rizzo A; Cavalloni G; Aglietta M Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824407 [TBL] [Abstract][Full Text] [Related]
5. Preclinical and clinical studies of immunotherapy for the treatment of cholangiocarcinoma. Lu X; Green BL; Xie C; Liu C; Chen X JHEP Rep; 2023 Jul; 5(7):100723. PubMed ID: 37229173 [TBL] [Abstract][Full Text] [Related]
6. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted. Vallejo A; Erice O; Entrialgo-Cadierno R; Feliu I; Guruceaga E; Perugorria MJ; Olaizola P; Muggli A; Macaya I; O'Dell M; Ruiz-Fernandez de Cordoba B; Ortiz-Espinosa S; Hezel AF; Arozarena I; Lecanda F; Avila MA; Fernandez-Barrena MG; Evert M; Ponz-Sarvise M; Calvisi DF; Banales JM; Vicent S J Hepatol; 2021 Aug; 75(2):363-376. PubMed ID: 33887357 [TBL] [Abstract][Full Text] [Related]
7. Epidemiology of cholangiocarcinoma. Qurashi M; Vithayathil M; Khan SA Eur J Surg Oncol; 2023 Sep; ():107064. PubMed ID: 37709624 [TBL] [Abstract][Full Text] [Related]
8. Developing models of cholangiocarcinoma to close the translational gap in cancer research. Waddell SH; Boulter L Expert Opin Investig Drugs; 2021 Apr; 30(4):439-450. PubMed ID: 33513027 [No Abstract] [Full Text] [Related]
9. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma. Lapitz A; Azkargorta M; Milkiewicz P; Olaizola P; Zhuravleva E; Grimsrud MM; Schramm C; Arbelaiz A; O'Rourke CJ; La Casta A; Milkiewicz M; Pastor T; Vesterhus M; Jimenez-Agüero R; Dill MT; Lamarca A; Valle JW; Macias RIR; Izquierdo-Sanchez L; Pérez Castaño Y; Caballero-Camino FJ; Riaño I; Krawczyk M; Ibarra C; Bustamante J; Nova-Camacho LM; Falcon-Perez JM; Elortza F; Perugorria MJ; Andersen JB; Bujanda L; Karlsen TH; Folseraas T; Rodrigues PM; Banales JM J Hepatol; 2023 Jul; 79(1):93-108. PubMed ID: 36868481 [TBL] [Abstract][Full Text] [Related]
10. Selecting an Appropriate Experimental Animal Model for Cholangiocarcinoma Research. Li M; Zhou X; Wang W; Ji B; Shao Y; Du Q; Yao J; Yang Y J Clin Transl Hepatol; 2022 Aug; 10(4):700-710. PubMed ID: 36062286 [TBL] [Abstract][Full Text] [Related]
11. Cholangiocarcinoma-on-a-chip: A human 3D platform for personalised medicine. Polidoro MA; Ferrari E; Soldani C; Franceschini B; Saladino G; Rosina A; Mainardi A; D'Autilia F; Pugliese N; Costa G; Donadon M; Torzilli G; Marzorati S; Rasponi M; Lleo A JHEP Rep; 2024 Jan; 6(1):100910. PubMed ID: 38074504 [TBL] [Abstract][Full Text] [Related]
12. Overcome Drug Resistance in Cholangiocarcinoma: New Insight Into Mechanisms and Refining the Preclinical Experiment Models. Zheng Q; Zhang B; Li C; Zhang X Front Oncol; 2022; 12():850732. PubMed ID: 35372014 [TBL] [Abstract][Full Text] [Related]
13. Animal models of cholangiocarcinoma. Ko KS; Peng J; Yang H Curr Opin Gastroenterol; 2013 May; 29(3):312-8. PubMed ID: 23434850 [TBL] [Abstract][Full Text] [Related]
14. Identification of SPRYD4 as a tumour suppressor predicts prognosis and correlates with immune infiltration in cholangiocarcinoma. Ma Z; Xie T; Sun J; Yu J; Huang S; Zhou Q; Li B BMC Cancer; 2023 May; 23(1):404. PubMed ID: 37142983 [TBL] [Abstract][Full Text] [Related]
16. Experimental models to unravel the molecular pathogenesis, cell of origin and stem cell properties of cholangiocarcinoma. Vicent S; Lieshout R; Saborowski A; Verstegen MMA; Raggi C; Recalcati S; Invernizzi P; van der Laan LJW; Alvaro D; Calvisi DF; Cardinale V Liver Int; 2019 May; 39 Suppl 1():79-97. PubMed ID: 30851232 [TBL] [Abstract][Full Text] [Related]
17. Development of potent antibody drug conjugates against ICAM1 Zhu B; Wang X; Shimura T; Huang AC; Kong N; Dai Y; Fang J; Guo P; Ying JE NPJ Precis Oncol; 2023 Sep; 7(1):93. PubMed ID: 37717087 [TBL] [Abstract][Full Text] [Related]